Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

The Development Of Mechanosensitivity
Researchers of the Max DelbrÃøck Center for Molecular Medicine (MDC) Berlin-Buch, Germany, have gained crucial insight into how mechanosensitivity arises. By measuring electrical impulses in the sensory neurons of mice, the neurobiologists and pain researchers Dr. Stefan G. Lechner and Professor Gary Lewin were able to directly elucidate, for the first time, the emergence of mechanosensitivity. At the same time they were able to show that neurons develop their sensitivity to touch and pain during different developmental phases but always coincidentally with the growth of the neuronal pathways. (EMBO Journal, 2009, doi:10.1038/emboj.2009.73).*

Array BioPharma Advances Its Lead MEK Inhibitor Into Cancer
Array BioPharma Inc. (NASDAQ: ARRY) announced the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration to initiate a Phase 1 clinical trial in cancer patients with its most advanced wholly owned MEK inhibitor, ARRY-162. Recent research confirms that the MEK pathway acts as a central axis in the proliferation of different tumors including melanoma, non-small cell lung, head/neck and pancreatic cancers. Array plans to simultaneously develop ARRY-162 for the treatment of both cancer and inflammatory disease. Array is currently completing a worldwide Phase 2, double-blinded clinical trial with ARRY-162 in 200 patients with active rheumatoid arthritis.
News of the day
Could Estrogen Improve Outcomes After Traumatic Brain Injury, Shock?
UT Southwestern Medical Center researchers are conducting two pilot clinical trials to determine whether a single, early dose of estrogen can improve survival and neurological outcomes after severe traumatic brain injury or traumatic hemorrhagic shock.
Health Insurance

RISPERDAL CONSTA (risperidone) Long-Acting Treatment May Improve Health Outcomes And Reduce Hospitalizations In Patients With Schizophrenia

Schizophrenia is one of the most disabling diseases, and frequent relapses and rehospitalization as a result of the disease place enormous burdens on patients, caregivers and society. According to two new studies, the use of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment (RLAT) may improve clinical and functional outcomes and reduce rates of rehospitalization among patients with schizophrenia. Results of the studies were presented this week at a major medical meeting. In an analysis of two prospective, observational two-year studies conducted in the U.S. and three other countries, RISPERDAL® CONSTA® consistently and significantly improved clinical and functional outcomes for patients with schizophrenia. Data were collected at baseline and at three-month intervals up to 24 months, and included the Clinical Global Impression of Illness Severity (CGI-S), which measures clinical effectiveness outcomes, the Global Assessment of Functioning (GAF), and healthcare re utilization. Patients were enrolled in the U.S. (N=532), Spain (N=1345), Australia (N=784) and Belgium (N=408). Across countries, patients treated with RISPERDAL® CONSTA® experienced significant improvements in both outcome measurements compared with baseline scores (p7% of baseline body weight) was 6% placebo versus 9% RISPERDAL® CONSTA®. Maintenance Treatment: Patients should be periodically reassessed to determine the need for continued treatment. Commonly Observed Adverse Reactions for RISPERDAL® CONSTA®: The most common adverse reactions in clinical trials in patients with schizophrenia (ò‰¥5%) were headache, Parkinsonism, dizziness, akathisia, fatigue, constipation, dyspepsia, sedation, weight increase, pain in extremities, and dry mouth. The most common adverse reactions in clinical trials in patients with bipolar disorder trials were weight increase (5% in monotherapy trial) and tremor and parkinsonism (ò‰¥10% in adjunctive therapy trial). Lesley Fishman Johnson & Johnson


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009